Hemoglobinopathies
Submission Deadline: Nov. 20, 2019

This special issue currently is open for paper submission and guest editor application.

Join as Guest Editor Submit to Special Issue
Lead Guest Editor
Tamer Hassan
Zagazig University, Zagazig, Egypt
Guest Editor
  • Galila Mokhtar
    Ain Shams University
    Cairo, Egypt
Guidelines for Submission
Manuscripts can be submitted until the expiry of the deadline. Submissions must be previously unpublished and may not be under consideration elsewhere.
Papers should be formatted according to the guidelines for authors (see: http://www.sciencepublishinggroup.com/journal/guideforauthors?journalid=395). By submitting your manuscripts to the special issue, you are acknowledging that you accept the rules established for publication of manuscripts, including agreement to pay the Article Processing Charges for the manuscripts. Manuscripts should be submitted electronically through the online manuscript submission system at http://www.sciencepublishinggroup.com/login. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal and will be listed together on the special issue website.
Published Papers
The special issue currently is open for paper submission. Potential authors are humbly requested to submit an electronic copy of their complete manuscript by clicking here.

Special Issue Flyer (PDF)

Please download to know all details of the
Special Issue

Introduction
Hemoglobinopathies are defined as inherited qualitative or quantitative abnormalities of globin synthesis. Thalassemias are generally caused by inadequate quantities of the polypeptide chains that form hemoglobin and the most frequent forms of thalassemia are therefore the α and β-thalassemias. In Sickle cell Anemia, the E6V (glutammic acid to valine at codon 6) mutation replaces a polar by a neutral amino acid on the outer surface of the b-globin molecule. The red blood cells of people with sickle cell disease contain an abnormal type of hemoglobin, called hemoglobin S. There are also some clinically significant variant hemoglobin including hemoglobin C, hemoglobin E, hemoglobin constant spring, hemoglobin Barts and hemoglobin H.

Aims and Scope:

  1. Beta thalassemia Major
  2. Non transfusion dependent thalassemias (NTDT) including thalassemia intermedia
  3. Alpha Thalassemia
  4. Sickle cell Anemia
  5. Other structural hemoglobinopathies including and not limited to Hemoglobin C and Hemoglobin E diseases.
  6. Genotype phenotype relationship in thaassemias
  7. Updates in diagnosis of hemoglobinopathies
  8. Updates in treatment of hemoglobinopathies
  9. Genetic diagnosis of hemoglobinopathies
  10. Prenatal and Preimplantation genetic diagnosis
  11. Hematopoietic stem cell transplantation in hemoglobinopathies
  12. Updates in assessment of iron overload in hemoglobinopathies
  13. Updates in ion chelation in hemoglobinopathies
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186